I think the point is that they use an in-house generic, priced at their normal revenue, to get a 180d monopoly and establish a second brand. This is all on top of their existing monopoly from the original patent.
That's quite scummy, but presumably the examples in the article have already lost their competitive edge? The EpiPen authorized generic was launched roughly 3 years ago.